Introduction
Chromosomal instability (CIN) is a key mechanism resulting in genomic changes associated with tumorigenesis (Geigl et al., 2008) . In many cancer cells, CIN is associated with chromosomal and centrosomal amplification. Tetraploidy, or twice the normal number of chromosomes, has been observed in some cancers, such as myeloid leukemia, malignant gliomas, colonic adenocarcinoma, (Park et al., 1995; Takanishi et al., 1996; Lemez et al., 1998) and tumor-derived cell lines (Shi and King, 2005; Olaharski et al., 2006) . Shackney et al. (1989) have shown that one of the earliest events in human tumor formation is the development of tetraploidy. In addition, Pellman and coworkers found that tetraploidy in primary cells lacking p53, caused by an experimentally induced failure of cytokinesis, promotes tumorigenesis in mice (Fujiwara et al., 2005) . In addition to increased chromosome number, cytokinesis failure also leads to centrosomal amplification producing multipolar mitotic spindles that cannot segregate their chromosomes evenly (Nigg, 2006; King, 2008) . Centrosomal amplification is also common in tumor cells, is associated with a more severe prognosis, and centrosomal amplification causes tumor formation in model systems (Sluder and Nordberg, 2004; Wang et al., 2004) . These observations suggest that failure of cytokinesis, and the associated chromosomal and centrosomal amplification, could have an important role in human cancer.
Although much is known about the basic mechanisms of cytokinesis, how cytokinesis failure contributes to tetraploidy in cancer cells is still unknown. Cytokinesis begins in the late anaphase with the assembly of a transient structure known as the contractile ring at the equator between the spindle poles. Contraction occurs during the telophase, driven by an actin-myosin molecular motor system, and results in the formation of a cleavage furrow. Nonmuscle myosin II is composed of a heavy chain and essential and regulatory light chains (myosin regulatory light chain, MLC). In higher eukaryotes, cellular myosin is activated by the phosphorylation of MLC at Thr18/Ser19 (Komatsu et al., 2000) . The phosphorylation at MLC Ser19 is critical for filament assembly; however, diphosphorylation at Thr18 and Ser19 promotes the interaction of myosin with the actin at the cleavage furrow (Scholey et al., 1980; Ikebe et al., 1988) . Komatsu et al. (2000) showed that the expression of unphosphorylated MLC in mammalian cells caused failure of cytokinesis. Thus, MLC phosphorylation is one of the key processes regulating contractile ring formation and completion of cytokinesis.
Myosin light-chain kinase (MLCK) and myosin phosphatase are known as critical enzymes that regulate myosin phosphorylation. MLCK phosphorylates MLC on both Ser19 and Thr18 (Ikebe and Hartshorne, 1985) . MLCK localizes at cleavage furrows (Poperechnaya et al., 2000) , and inhibition of cleavage furrow contractility is observed with either the MLCK inhibitory peptide or ML-7, a specific MLCK inhibitor in sea urchin eggs and crane-fly primary spermatocytes (Silverman-Gavrila and Forer, 2001; Lucero et al., 2006) . In addition, ROCK, a Rho-effector kinase, and citron kinase also regulate MLC phosphorylation in cytokinesis (Amano et al., 1996; Kosako et al., 1999; Eda et al., 2001) . Myosin phosphatase is the only known phosphatase that regulates MLC and MYPT1 is the targeting subunit (Ito et al., 2004) . Misregulation of any of these kinases or MYPT1 could influence MLC phosphorylation in cancer cells and potentially contribute to cytokinesis failure and chromosome instability.
In this research report, we examine the failure of cytokinesis in cancer cells and the fate of cells with multipolar spindles (MPSs) by real-time microscopic imaging. We observe that cell divisions fail in cancer cells, resulting in multinucleated cells (a single cell with two or more than two nuclei), which divide with MPSs in the next cell cycle. Furthermore, we investigate the causes of defective cytokinesis in cancer cells. In this study, we show that failure of cytokinesis in cancer cell lines is correlated with low levels of MLC phosphorylation. Phosphorylation reduction is caused by increased MYPT1 and decreased MLCK in oral cancer cells. When MLC phosphorylation was restored to high levels, cytokinesis failure and multipolar division were reduced in oral and liver cancer cells. In addition, both overexpression of MYPT1 and inhibition of MLCK in primary cells increased multinucleation and MPSs defects. In conclusion, our results show for the first time that cytokinesis failure in cancer cells are caused by deficiencies in myosin light-chain phosphorylation, which is due to the reduction of MLCK, as well as elevation of myosin phosphatase.
Results

MPS formation associated with failure of cytokinesis
To investigate the origin of MPS formation in aneuploid cells, cell divisions of human embryonic kidney cell (HEK)-293 and human OSCC tumor cells (UPCI:SCC103) were examined by DIC or fluorescent live-cell microscopy. Both cell lines were transiently transected with plasmids expressing green fluorescent protein (GFP)-histone H2B and farnesylated-GFP to visualize the cell nuclei and membrane, respectively. We observed that >90% of MPSs arose in multinucleated cells in both tested cell lines (defined as cells with two or more nuclei, Supplementary Figure 1a) , commonly resulting from cytokinesis failure. In addition, the great majority of multinucleated cells observed to form in these cells were due to a failure of cytokinesis Figure 2) . These data confirm that a failure of cytokinesis is observed in these aneuploid cell lines, followed by a multipolar cell division.
MLC phosphorylation is deficient in cancer cells
To dissect where the cells failed in cytokinesis, UPCI:SCC103 cells were transfected with a plasmid expressing GFP-actin and examined by live-cell microscopy to view the cleavage furrow and contractile ring formation. The recombinant GFP-actin colocalized with myosin, suggesting that the protein is active (Supplementary Figure 3a) . We observed that 8.1% of UPCI:SCC103 cells failed in cytokinesis (n ¼ 62) and most exhibited cleavage furrow and contractile ring formation defects (Supplementary Figure 3b , Supplementary Movies 3a and b), suggesting that these cancer cells primarily failed at an early stage of cytokinesis with abnormal contractility.
MLC phosphorylation at Thr18/Ser19 is one of the key regulatory steps in contractile ring formation and contractility (Moussavi et al., 1993; Komatsu et al., 2000) . We observed that phosphorylation of MLC in cancer cells was different from normal cells. Cancer cells universally showed low levels of MLC phosphorylation compared with normal cells (Po0.001) (Figure 2a ). All tested noncancer cell lines, RPE-hTERT (retinal pigment epithelial cells immortalized with human telomerase, hereafter RPE1), fibroblast and OKF-hTERT (normal human oral keratinocyte immortalized with human telomerase) showed high MLC phosphorylation but low multinucleation frequency, whereas the tested different cancer cell lines clustered in the area of low MLC phosphorylation and high multinucleation (Figure 2b ). These observations suggest that the deficiency in MLC phosphorylation could be a cause of cytokinesis failure in cancer cells.
To test this hypothesis, the phosphorylation of MLC was examined in UPCI:SCC103 cells and compared with primary RPE1 cells. We first determined whether MLC phosphorylation was induced during mitosis in cancer cells. UPCI:SCC103 and RPE1 cells were synchronized at metaphase by Colcemid and released for different time points. The phosphorylation of MLC was increased in mitosis of both cell types. However, the level of phosphorylation declined more rapidly in cancer cells (Supplementary Figure 3c) . The lower levels of MLC phosphorylation in mitotic cancer cells is partially obscured by the higher frequency of mitotics in tumor lines. Therefore, to further compare the MLC phosphorylation levels in the different cell types, we compared by immunofluorescence the relative intensity of the phosphoepitope of MLC (Figure 2c, left panel) .
These results are consistent with diminished MLC phosphorylation in cancer cells during division. Furthermore, the phosphorylated MLC in cancer cells did not colocalize completely with the myosin heavy chain (Figure 2c , right panel). In conclusion, we observed that failure of cytokinesis in cancer cell lines was associated with decreased phosphorylation of MLC during mitosis.
MLC phosphorylation deficiency causes cytokinesis failure in oral cancer cells
To test whether the deficiency of phosphorylation of MLC is the cause of the defective contractile ring and failed cytokinesis in tumor cells, a phosphomimetic MLC plasmid (Thr18 and Ser19 were replaced with Asp) was transfected into UPCI:SCC103 cells. This recombinant MLC protein expressed abundantly and localized properly with the myosin heavy chain, the same as wild-type MLC (Supplementary Figure 3d) . Multinucleation frequency decreased marginally, but statistically significantly, after phosphomimetic MLC expression in oral cancer cells (Figure 2d, Po0.01 ). This modest reduction may be due to residual multinucleated cells in the population. Therefore, to test the frequency of cytokinesis failure more directly, UPCI:SCC103 cells were visualized by live microscopy. Cell division failure decreased markedly after introduction of the phosphomimetic MLC compared with control cells with wild- 
Myosin phosphatase is an important regulator of MLC phosphorylation and cytokinesis completion in cells
To understand why MLC phosphorylation is decreased in malignant cells, MLC kinases and phosphatase expression was examined by immunoblotting. ROCK1 expressions showed no consistent differences between normal and cancer cells (Figure 3) , and citron kinase expression overall was low (data not shown). In addition, defective ROCK1 or overexpression of citron kinase has not previously been shown to cause contractile ring defects (Madaule et al., 1998; Kosako et al., 1999) . On the other hand, MYPT1, the myosin-targeting subunit, showed upregulated expression in many of the tested cell lines (Figure 3 ). Hence, we designed a small interfering RNA (siRNA) targeting MYPT1, to knock down the targeting subunit in tumor cells (Supplementary Figure 4a) . Figure 4b) . When the phosphorylation levels increased, the multinucleation frequency decreased (Figure 4b , Po0.01).
To confirm that this reduction is due to the downregulation of myosin phosphatase subunit and not by other off-target effects, a recombinant siRNA-resistant chicken MYPT1 protein was expressed in siMYPT1-treated UPCI:SCC103 cells. This recombinant MYPT1-GFP protein colocalized with endogenous myosin heavy chain and the expression restored multinucleation to untreated levels ( Figure 4b and Supplementary  Figure 4a ). MYPT1 knockdown did not cause significant apoptosis or changes in the mitotic index (data not shown). These results indicated that the multinucleation in the OSCC cell line was caused by decreased MLC phosphorylation, resulting from MYPT1 overexpression. To confirm that the reduction in multinucleation was caused by a correction of cytokinesis defects, we examined cell divisions by live-cell imaging.
The frequency of cytokinesis failure in bipolar cell divisions in UPCI:SCC103 cells decreased from 8.4 to 3.2% after MYPT1 downregulation by siRNA treatment ( Figure 4c ). We hypothesized that the extended siMYPT1 treatment in UPCI:SCC103 cells would sharply reduce the multinucleation and spindle multipolarity defects in these cells. We observed that both Cytokinesis failure and multipolarity in cancer cells Q Wu et al multinucleation and multipolarity were markedly decreased after a 20-day siMYPT1 treatment compared with scrambled-siRNA treatment controls (Figure 4d , Po0.005, Supplementary Figure 4c ). In addition, CIN was measured by the frequency of the deviation from the modal number of chromosomes after MYPT1 was knocked down in oral cancer cells (Thompson and Compton, 2008) . Consistent with the reduction in spindle defects, CIN was also reduced (Figure 4e , Supplementary Table 1 ), indicating that defective MLC phosphorylation and failed cytokinesis is a major cause of multinucleation, multipolarity and CIN in these oral cancer cells. Next, we asked whether the MYPT1 expression was also the cause for multinucleation in other cancer types. Another cancer cell line (SK-HEP1), with relatively low levels of MYPT1 expression was tested with siRNA knockdown. Similar to oral cancer cells, liver cancer cells showed decreased multinucleation and multipolarity percentages after a 20-day siMYPT1 treatment (Supplementary Figure 4d) , suggesting that elevated myosin phosphatase activity is a cause of cytokinesis failure in different tumor cell types.
We next asked whether overexpression of MYPT1 was sufficient to cause cytokinesis failure and result in multinucleation in nonmalignant cells. Full-length chicken MYPT1 fused with GFP was transiently expressed in RPE1 cells. After MYPT1-GFP overexpression, multinucleation frequency increased approximately fourfold (Figure 5a, Po0.005) . Similarly, overexpression of MYPT1 in UPCI:SCC103 cells gave rise to additional multinucleated cells (Figure 5b , Po0.005). HEK-293 cells stably expressing the MYPT1-GFP protein also showed elevated multinucleation and multipolarity frequencies (data not shown). 
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Taken together, these results indicate that the overexpression of MYPT1 is an essential and sufficient cause of multinucleation and multipolarity in cancer cell lines.
MLCK is downregulated and inhibited in oral cancer cells
We observed that MLC phosphorylation was defective in oral cancer cells and resulted in cytokinesis failure. Therefore, we hypothesized that cytokinesis would be rescued if we restored the expression and activity of MLCK in oral cancer cells. To test this hypothesis, the MLCK-EGFP protein was expressed in UPCI:SCC103 cells (Supplementary Figure 6a) . To confirm activity of the MLCK-EGFP fusion protein, MLCK was immunoprecipitated from whole-cell lysates, and MLCK activity assays were performed in vitro (Poperechnaya et al., 2000) . ML-7, an MLCK specific inhibitor, was used to show specificity of the assay (Supplementary Figure 5a) . Recombinant MLCK-EGFP was as active as endogenous MLCK by the MLC phosphorylation assay in vitro (Supplementary Figures 5b and c) . However, the MLC phosphorylation ratio did not UPCI:SCC103 cells were treated by siMYPT1, and phosphorylation of MLC was examined by urea glycerol gel electrophoresis. The data were means ± s.d. from more than three experiments. (b) Multinucleation frequency was reduced by siMYPT1 knockdown and was restored by resistant MYPT1-GFP protein expression in oral cancer cells (*Po0.01). UPCI:SCC103 cells were treated by siMYPT1 and transfected with resistant MYPT-GFP plasmids. Cells with both siRNA and plasmid were quantitated for multinucleation. The data were means±s.d. from more than three experiments. (c) MYPT1 knockdown markedly rescued cytokinesis failure in oral cancer cells. UPCI:SCC103 cells were transfected with siMYPT1. Bipolar cell divisions were examined by DIC time-lapse microscopy. (d) Multinucleation and multipolarity were reduced after a 20-day siMYPT1 treatment in oral cancer cells (*Po0.005, **Po0.005). The data were means ± s.d. from more than three experiments. UPCI:SCC103 cells were treated with siMYPT1 for 20 days. Multinucleation and multipolarity were quantified every 4 days. (e) Chromosomal instability was reduced after a 20-day siMYPT1 treatment in oral cancer cells. The copy number of chromosomes 6 and 20 were enumerated by FISH. Modal chromosome numbers were chosen as the value that occurred the most frequently in each cell type. The frequency of deviation from the mode was calculated by the percentage of nonmodal number in each cell type, which was used to measure the chromosomal instability of the cell.
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Q Wu et al increase in these cells (Supplementary Figure 6b) . Furthermore, we observed no reduction, but an increase in multinucleation (Figure 6a ), and no change in cytokinesis failure or contractile ring defects (Supplementary Figure 6c ; Supplementary Movies 4a and b). This suggested that MLCK might be inhibited in UPCI:SCC103 cells. To confirm this hypothesis, equal amounts of endogenous MLCK was immunoprecipitated from UPCI:SCC103 and RPE1 cells and MLCK activity was compared in vitro. MLCK activity in oral cancer cells was lower than that in noncancer, but also epithelial origin, RPE cells (Figure 6b ), indicating that MLCK was inhibited in UPCI:SCC103 cells. Similarly, MLCK immunoprecipitated from primary fibroblasts showed more activity than did U2OS cells, both cell lines of mesenchymal origin (Supplementary Figure 5d) . Taken together, these results show that both MLCK expression and activity are downregulated in oral cancer cells. To examine whether MLCK inhibition is sufficient to block the completion of cytokinesis in nonmalignant cells, RPE1 cells were treated with 35 mM ML-7 for 48 h. Stress fibers disappeared and MLC phosphorylation decreased sharply (Supplementary Figures 7a and b) , which was not due to reduced expression of endogenous MLC (Supplementary Figure 7c) . Furthermore, multinucleation increased to B7% after 48-and 72-h ML-7 treatment (Figure 6c, Po0.005 ). This multinucleation phenotype was diminished when RPE1 cells were released after 72-h treatment (Figure 6c) . These results confirmed that a reduction in MLCK activity in nontransformed cells could reproduce MLC phosphorylation defects and multinucleation seen in malignant cells.
Discussion
Polyploidy is an important characteristic of major solid tumor tissues and tumor-derived cells (Park et al., 1995; Takanishi et al., 1996; Lemez et al., 1998; Lothschutz et al., 2002; Shi and King, 2005; Olaharski et al., 2006) . The data presented in this study show that cytokinesis failure is a primary mechanism for the increased ploidy of oral carcinoma cells and the molecular defects leading to cytokinesis failure in these and other cancer cell types. We present the following four lines of evidence to support this conclusion: (1) The ratios of MLC phosphorylation are universally reduced, and this reduction is correlated with increased multinucleation in the tested cancer cell lines. (2) Phosphomimetic MLC overexpression overcomes the endogenous defective MLC phosphorylation and rescues cytokinesis failure. (3) When MLC phosphorylation is restored to normal levels by phosphatase knockdown, cytokinesis failure and multinucleation decreases. Finally, (4) the reduction of MLC phosphorylation by phosphatase overexpression or MLCK inhibition is sufficient to cause multinucleation and multipolar mitoses in nonmalignant cells. These results show that decreased MLC phosphorylation is an important cause of cytokinesis failure in cancer cells, resulting in multinucleation and multipolar division.
Pellman and colleagues have shown that the tetraploid p53-null cells generate malignant myoepitheliomas in nude mice. They have linked cytokinesis failure to carcinogenesis for the first time in vivo (Fujiwara et al., 2005) . However, the manner by which cytokinesis fails in cancer cells remains unclear. On the basis of the results of this study, we propose a model of the mechanism for the accumulation of multinucleated cells: in normal cells, MLC phosphorylation is regulated by MLCK and myosin phosphatase at the appropriate time during mitosis to ensure the completion of cytokinesis. If the balance of MLC phosphorylation is changed by MLCK inhibition or myosin phosphatase overexpression, cytokinesis fails early in division, leading to multinucleated cells. These cells inherit extra centrosomes causing them to divide with MPSs in the next mitosis. By going into multipolar cell division, mother multinucleated cells usually generate a mixture of multinucleated and mononucleated daughter cells. These multinucleated cells could enter a new cell cycle Cytokinesis failure and multipolarity in cancer cells Q Wu et al or apoptosis. The mononucleated cells are likely to inherit one centrosome and an abnormal chromosome set, which may lead to a 'normal' bipolar cell division in the next cell cycle and contribute to a stable genome change (Figure 6d ). Recent microarray analyses have shown that MLCK gene expression is low in various tumors, such as colon, lung, prostate, bladder, brain, breast, ovarian, liver, melanoma and multiple myeloma, compared with normal controls (http://www.oncomine.org) (Rhodes et al., 2007) . Downregulated MLCK transcription and expression is also observed in mesenchymal tumor cells and transformed chicken embryo fibroblasts, respectively (Van Eldik et al., 1984; Schenker and Trueb, 1998) . These results confirm that the inhibited MLCK we observe in cancer cell lines is also relevant for tumor tissue. When we increased the level of phosphorylated MLC in the MLCK-downregulation background by (Amano et al., 1996; Kosako et al., 1999; Eda et al., 2001) . However, we did not detect significant consistent differences of ROCK1 and citron kinase expressions in the tested cell lines (Figure 3 , data not shown). Moreover, we also examined the RhoA expression, which is the activator of ROCK and citron kinase, and observed the same levels in cancer cells compared with normal cells (data not shown). However, we cannot rule out that defective cytokinesis in cancer cells is also influenced by abnormal regulations of these kinases.
The regulation of phosphorylation is a major target of cancer therapeutics, and the data presented in this study suggest MLC as a potential candidate. However, myosin activity is relevant to many aspects of cellular growth and survival. It has been shown that the MLCK inhibitor, ML-7, prevents the growth of tumors in mice and rats, which might be caused by less motility and adhesion due to decreased MLC phosphorylation (Kaneko et al., 2002; Tohtong et al., 2003; Gu et al., 2006) . However, our data suggest that therapeutic MLCK inhibition might also result in an increase in cytokinesis defects and aneuploidy, which would constitute a serious side effect and cause severe problems in long-term human therapy. The other potential regulatory candidate is MYPT1. On the basis of our studies, we concluded that downregulation of MYPT1 rescues cytokinesis failure and reduces CIN in cancer cells. Interestingly, Xia et al. (2005) have shown that knockdown of MYPT1 in HeLa cells inhibits cell migration and adhesion. Taken together, these findings suggest that an inhibitor of MYPT1 might be a useful potential target for cancer therapy.
Materials and methods
Cell culture ATCC (American Type Culture Collection, Manassas, VA, USA) cell lines, HCT116, SK-HEP1, U2OS, HeLa, MES-SA, A549, Human fibroblast (CCL-110), HEK-293, RPE1, were cultured in the medium recommended by the supplier. Oral cancer cell lines, UPCI:SCC103 and UPCI:SCC078 were maintained in minimal essential medium (Sigma, St Louis, MO USA), supplemented with 10% fetal bovine serum (Atlanta Biochemicals, Lawrenceville, GA, USA), 2 mM L-glutamine, 0.05 mg/ml gentamycin and 1% nonessential amino acids (Invitrogen, Carlsbad, CA, USA) (White et al., 2007) . All cells were incubated at 37 1C in 5% CO 2 .
DNA transfection and RNA interference Cells were transfected with 1-2 mg of DNA plasmids as follows by using 6 ml FuGENE6 transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) per coverslip according to the manufacture's protocol. Cells were lysed or fixed after 22-h transfection. Site-directed mutagenesis to create the siRNAresistant silent mutant of GFP-MYPT1 was performed using primers 5 0 -CAGAGACAAGAGCGGTTTGCTGACAG-3 0 and 5 0 -CTGTCAGCAAACCGCTCTTGTCTCTG-3 0 . siMY PT1 (5 0 -GAGACAAGAAAGATTTGCT-3 0 , Dharmacon, Lafayette, CO, USA) (Xia et al., 2005) or the control rhodamine siRNA (Qiagen, Germantown, MD, USA) was performed using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's recommendations. For the 20-day MYPT1 knockdown, cells were seeded on day 0 and siRNA treatment started on day 1. On day 4, half of the cells were analyzed, whereas the other half were seeded again and the second knockdown cycle started. The whole knockdown process lasted for 20 days. After 20 days, cells were cultured in a fresh culture medium without any siRNA for 4 days and analyzed as released cells.
Phosphorylated MLC localization detection
Cells on coverslips were fixed in 3.7% formaldehyde at room temperature and cold acetone at À20 1C. Primary antibodies mAb-phosphorylated Ser19-MLC (Cell Signaling, Danvers, MA, USA) and rAb-myosin heavy chain (Sigma) were diluted in phosphate-buffered saline Tween-20 and incubated overnight at 4 1C. Cells were incubated with secondary antibodies (Invitrogen) and DAPI (Sigma) at room temperature for 2 h.
Immunoprecipitation and MLCK activity assay
Whole-cell lysates were incubated with monoclonal mouse MLCK antibody (Sigma) at 4 1C for 2 h. After 2 h, Protein A sepharose beads (Amersham Biosciences, Piscataway, NJ, USA) were added and incubated at 4 1C for 2 h. Immunoprecipitates were split into two halves. One half of the sample was electrophoresed for immunoblotting. The other half was resuspended in a kinase reaction mixture containing 10 mM MOPS, pH 7.0, 1 mM DTT (dithiothreitol), 4 mM MgCl 2 , 0.1 mM CaCl 2 , 1 mM calmodulin, 0.1 mM [g 32 P] ATP and 15 mM MLCK substrate (Sigma) (Poperechnaya et al., 2000) . A volume of 10 ml reaction mixture was removed at different time points and spotted onto 1 cm 2 squares of phosphocellulose (Upstate, Billerica, MA, USA). The squares were washed 10 times with 2 ml of 75 mM phosphoric acid and measured for incorporation of 32 P by scintillation counter.
MLC phosphorylation analysis MLC phosphorylation was measured by urea/glycerol-PAGE and immunoblotting as described previously (Word et al., 1991) . Cells were seeded on 6-well plates and harvested by 0.5 ml ice-cold trichloroacetic acid containing 10 mM DTT. The pellets were washed three times with diethyl ether and resuspended with 8 M urea, 20 mM Tris-HCl, 23 mM glycine, 10% glycerol, 10 mM EGTA, 1 mM EDTA and 0.2% bromophenol blue (pH 8.6).
Fluorescence in situ hybridization Four 'blinded' flasks of cultured cells labeled, UPCI:SCC103A through D were treated with Colcemid (0.1 mg/ml) for 5 h before harvesting. After mitotic arrest, the cells were processed in accordance with standard cytogenetic laboratory procedures and slides were prepared for cytogenetic analysis. Fluorescence in situ hybridization assays were carried out to determine chromosome copy-number changes. Two CEPs (chromosome enumeration probes), CEP6 labeled with Spectrum Green and CEP20 labeled with Spectrum Orange (Abbott Molecular Inc., Des Plaines, IL, USA) were randomly selected. Slides were pretreated with RNase, dehydrated in an ethanol series, denatured in 70% formamide and hybridized overnight at 37 1C in a humidified chamber. Posthybridization washes were carried out according to the protocol by Abbott Molecular
Inc. The slides were stained with DAPI and mounted with antifade. At least 500 metaphase cells and interphase nuclei were analyzed for each of the four conditions. All fluorescence in situ hybridization analyses were carried out using an Olympus BX61 epifluorescence microscope (Olympus Microscopes, Melville, KY, USA). The Genus software platform on the Cytovision System was used for image capture and analysis (Applied Imaging, San Jose, CA, USA).
Statistical analysis
All statistical analyses were performed using R statistical package (R version 2.4.1). Group comparisons were conducted by nonparametric Wilcox test. All P-values are one sided. Error bars indicate mean±s.d. of three different experiments.
